1Division of Oncology and 2Division of Endocrinology and Metabolism, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts; 4Fred Hutchinson Cancer Research Center, Seattle; 5Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington; 6Office of Cancer Clinical Proteomics Research, National Cancer Institute, NIH, Bethesda, Maryland; and 7The Jim Ayers Institute for Cancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Cancer Discov. 2013 Oct;3(10):1108-12. doi: 10.1158/2159-8290.CD-13-0219.
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.
美国国家癌症研究所（NCI）临床蛋白质组肿瘤分析联盟正在将最新一代蛋白质组技术应用于癌症基因组图谱（TCGA）计划中基因组注释的肿瘤，这是 NCI 和国家人类基因组研究所的联合倡议。通过提供个体肿瘤中 DNA、RNA 和蛋白质异常的全面综合说明，这些数据集将阐明基因组异常与癌症表型之间的复杂关系，从而产生生物学见解以及一系列新的候选生物标志物和治疗靶点，这些靶点可使用靶向质谱方法进行验证。
